Amunix grants Biogen exclusive, worldwide rights to discover, develop and commercialize Factor IX and VIII products to treat hemophilia using Amunix's recombinant XTEN technology

Amunix Operating Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Biogen Idec Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced